Ernexa Therapeutics (ERNA) vs Redhill Biopharma (RDHL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Redhill Biopharma is the larger company by market cap ($2.5 million vs $2.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ERNA | RDHL |
|---|---|---|
| Share price | $1.36 | $0.281 |
| Market cap | $2.30M | $2.50M |
| 1-day change | -16.56% | -13.08% |
| Forward P/E | — | 9.37 |
| EPS (TTM) | $-11.22 | $0.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $8.04M |
| Revenue growth (YoY) | — | +23.17% |
| Net income (latest FY) | $-14.08M | $-8.27M |
| Gross margin | — | 60.31% |
| Operating margin | — | -181.69% |
| Net margin | — | -102.80% |
| 52-week high | $37.50 | $1.60 |
| 52-week low | $1.35 | $0.281 |
| Distance from 52-week high | -96.37% | -82.44% |
| Analyst consensus | none | — |
| Avg. price target upside | +2105.88% | — |
| Average volume | 43.90K | 2.08M |
| Shares outstanding | 1.69M | 8.89M |
| Employees | 5 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ernexa Therapeutics
ERNA stock →Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Redhill Biopharma
RDHL stock →RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
ERNA vs RDHL FAQ
Which is bigger, Ernexa Therapeutics or Redhill Biopharma?
Redhill Biopharma (RDHL) is larger, with a market capitalization of $2.50M compared with $2.30M for Ernexa Therapeutics (ERNA).
Are Ernexa Therapeutics and Redhill Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.